Back
Astellas Up 38% YTD on Cancer Drug Success, Sparking Valuation Debate
Back
Stock News
Themes
Astellas Up 38% YTD on Cancer Drug Success, Sparking Valuation Debate
Astellas Up 38% YTD on Cancer Drug Success, Sparking Valuation Debate
Edgen Stock
·
Dec 22 2025, 18:08
Share to
Share to
Copy link
source:
[1] Reassessing Astellas Pharma (TSE:4503) Valuation After Positive PADCEV-Keytruda Phase 3 Bladder Cancer Results
Recommend
Celanese Q4 Earnings Plunge 54%, Missing Estimates
Feb 17 2026, 23:34
RB Global Beats Q4 Estimates With $1.11 EPS
Feb 17 2026, 23:33
Mercury General Crushes Q4 Forecasts With $3.66 EPS
Feb 17 2026, 23:32
Features
AI Copilot for Stock & Crypto
Price Prediction
Fundraise Tracker
Themes
Crypto Comparison
Home Page
Resources
Tutorial
Gitbook
Team
Aura Insights
Market
US Market
HK Market
Crypto Market
Terms of Use
Privacy Policy
Sitemap
© 2026 Finture Development Limited. All rights reserved
Edgen Stock·Dec 22 2025, 18:08Edgen Stock·Dec 22 2025, 18:08
Edgen Stock·Dec 22 2025, 18:08